Biodesixの空売り状況は、投資家がBiodesixの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Biodesix (NASDAQ:BDSX) 株価情報, 空売り情報

Biodesix

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

Biodesix Inc

<p><strong>Gorilla Technology Group Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) shares are trading higher on Tuesday, continuing on upward momentum after the company secured a $1.8 billion agreement to lead Thailand's largest energy digitization and infrastructure <a href="https://www.benzinga.com/news/contracts/25/03/44077705/why-is-gorilla-technology-stock-surging-today">overhaul on Monday.</a></p>
<p><strong>What To Know:</strong> The 15-year project aims to modernize Thailand's electricity grid using AI-powered technology to improve energy efficiency, enhance security and optimize power distribution. Gorilla Technology is adopting a new financing model that links revenue directly to efficiency improvements, moving away from traditional infrastructure funding approaches. This structure is expected to provide consistent, growing revenue over the project&#8217;s lifecycle, with a significant increase anticipated between 2026 and 2027 when full operations begin.</p>
<p>The company projects multi-billion-dollar cumulative revenue throughout the initiative. Gorilla's Sales Director for Thailand and the Rest of Asia, Mike Wang, highlighted that the program aligns with Thailand's national objective to build a resilient, technology-driven economy. </p>
<p><strong>GRRR Price Action: </strong>Gorilla. Technology shares were up 23.5% at $39.80 at the time of writing, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04140159/Screenshot-2025-03-04-at-14.01.33-1024x530.png" alt="" class="wp-image-808845" style="width:354px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04140159/Screenshot-2025-03-04-at-14.01.33-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04140159/Screenshot-2025-03-04-at-14.01.33-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04140159/Screenshot-2025-03-04-at-14.01.33-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/04140159/Screenshot-2025-03-04-at-14.01.33.png 1526w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44118620/whats-driving-markets-tuesday">Stocks Drop As Trade War Escalates: What&#8217;s Driving Markets Tuesday?</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


News

Movers

GRRR

Gorilla Technology Stock Jumps On $1.8 Billion Thailand Energy Deal

WIIM

Gorilla Technology Group shares are trading higher on continued strength after the company on Monday secured a $1.8 billion agreement to lead Thailand's smart grid and AI-Powered energy transformation.

<h2 class="wp-block-heading">Introduction to the FIRE Movement</h2>
<p>As made popular by Pete Adeney in 2011 via his <em>Mr. Money Mustache</em> blog, the FIRE movement stands for "Financial Independence, Retire Early."&nbsp;</p>
<p>It's a financial strategy where people aim to save and invest aggressively — <em>sometimes as much as 50-70% of their income</em> — so they can achieve financial independence and retire much earlier than the traditional retirement age of 65.&nbsp;</p>
<p>The strategy is simple — build a big enough nest egg that you can live off the returns, typically using something like the 4% withdrawal rule, as soon as possible.&nbsp;</p>
<p>This lifestyle has gained immense popularity among younger people who value freedom and flexibility over the standard 9-to-5 grind. The movement's momentum over the last few decades seemed to have been catalyzed by a "perfect storm" that included the Great Financial Crisis of 2008, digital platforms like Reddit and YouTube spreading the word, and a cultural shift toward valuing time over stuff.&nbsp;</p>
<p>With that being said, it took until November of 2024 for the first-of-its-kind FIRE Movement-focused ETF to be launched.&nbsp;</p>
<p>Introducing the <strong><em><a href="https://www.benzinga.com/quote/FIRS">FIRE Funds Wealth Builder ETF (FIRS)</a></em></strong> — designed to support your journey toward achieving financial independence, and hopefully an early retirement.&nbsp;</p>
<p><strong>In this post I'll dig into…</strong></p>
<ul>
<li>Exactly what FIRS is</li>
<li>Why FIRS exists</li>
<li>Who FIRS is for</li>
<li>Who is behind FIRS</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Exactly What FIRS Is</h2>
<p>The <a href="https://www.benzinga.com/quote/FIRS">FIRE Funds Wealth Builder ETF (FIRS)</a> is an investment product designed to support your journey toward achieving FIRE.&nbsp;</p>
<p>With a focus on resilience and potential growth across various market cycles, FIRS seeks long-term capital appreciation and diversification across four strategically constructed ETF baskets that align with the four most popular market conditions — Prosperity, Recession, Inflation, and Deflation.&nbsp;</p>
<p>This unique approach seeks to position your investments to respond effectively to changing economic environments — something bound to happen when you spend a decade or more focused on saving and building wealth via the US equity markets.&nbsp;</p>
<p>According to the fund's website, "FIRS aims to provide transparency, liquidity, and tax-efficiency, offering a streamlined option for those looking to align their investments with FIRE goals."&nbsp;</p>
<p>As we dig into the fund's prospectus, we learn that FIRS is a "fund of funds," which essentially just means it's an ETF composed of other ETFs.&nbsp;</p>
<p>As we read further, we learn about the fund's strategy — <em>a portfolio equally weighted among four baskets of Underlying ETFs designed to track the behavior of four distinct economic regimes.&nbsp;</em></p>
<p><strong>The four distinct economic regimes include:</strong></p>
<ul>
<li><strong>Prosperity</strong>, which will generally be comprised of Underlying ETFs that invest primarily in equity securities.&nbsp;</li>
<li><strong>Recession</strong>, which will generally consist of Underlying ETFs that aim to reduce risk and provide stable returns, take both long and short positions to seek profit from market fluctuations, and provide uncorrelated returns to the overall market.&nbsp;</li>
<li><strong>Inflation</strong>, which will generally be comprised of Underlying ETFs that primarily invest in commodities, real estate, and other inflation beneficiaries.&nbsp;</li>
<li><strong>Deflation</strong>, which will generally be comprised of Underlying ETFs that invest primarily in fixed income securities and bonds.&nbsp;</li>
</ul>
<p>As we dig further into the methodology used to select the Underlying ETFs, we learn that the <strong>Prosperity</strong> regime is benchmarked against the US equities via the <a href="https://www.benzinga.com/quote/VTI">Vanguard Total US Equity ETF (VTI)</a>, the <strong>Recession</strong> regime is benchmarked against Gold via the <a href="https://www.benzinga.com/quote/GLD">SPDR Gold Shares ETF (GLD)</a>, the <strong>Inflation</strong> regime is benchmarked against short-term treasuries via the <a href="https://www.benzinga.com/quote/SHY">iShares 1 to 3 Treasury Body ETF (SHY)</a>, and the <strong>Deflation</strong> regime is benchmarked against aggregate bonds via the <a href="https://www.benzinga.com/quote/AGG">iShares Core US Aggregate Bond ETF (AGG)</a>.&nbsp;</p>
<p>Portfolio construction is pretty straightforward. According to their prospectus, the FIRS ETF will hold between 10 and 25 Underlying ETFs with the overall goal of assigning a 25% weighting to each of the four regimes mentioned above.&nbsp;</p>
<p>Now that we're all on the same page as to what FIRS is, fundamentally speaking, let's explore why it exists in the first place.&nbsp;</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Why FIRS Exists</h2>
<p>As shared above, the FIRE movement encourages individuals to achieve financial independence by aggressively saving and investing with the goal of building a large enough nest egg they can retire early. Participants typically aim to reduce monthly expenses and accumulate substantial wealth through a combination of disciplined saving, consistently investing in growth-oriented assets, and optimizing portfolio construction to maximize returns over time.&nbsp;</p>
<p>There are two phases of the FIRE movement — the <strong>Wealth Accumulation</strong> phase and the <strong>Retirement</strong> phase.&nbsp;</p>
<p>They're exactly what they sound like. During the Wealth Accumulation phase you're building wealth. You're saving as much of your monthly income as you possibly can so that you can invest it into growth-oriented assets.</p>
<p>The FIRS ETF exists to optimize the Wealth Accumulation phase.</p>
<p>Through the Fund's four regime approach, it optimizes for long-term capital appreciation, offering a diversified mix of stocks, bonds, and other growth-oriented investments — no matter the market condition.&nbsp;</p>
<p>Then once you've accumulated enough wealth and hit your "FIRE Number," you can now implement the 4% Rule – enjoying your financial independence and retiring early.&nbsp;</p>
<p>Instead of trying to optimize your portfolio for these four common market conditions — <em>prosperity, recession, inflation, and deflation</em> — the FIRS ETF will automatically do this for you.&nbsp;</p>
<p>Let's now dig into who this ETF is specifically for.&nbsp;</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Who FIRS Is For</h2>
<p>Let's be real, if you're someone who's participating in the FIRE movement you're likely a money nerd. Being a money nerd, more often than not, also includes being a sophisticated investor — or at least the idea of learning about investing doesn't completely put you to sleep. In pursuit of becoming a sophisticated investor, I've spent thousands of hours learning about personal finance and investing over the last 10 years.&nbsp;</p>
<p>Now with the introduction of the <a href="https://www.benzinga.com/quote/FIRS">Fire Funds Wealth Building ETF (FIRS)</a>, you no longer have to be a sophisticated investor to optimize your Wealth Accumulation phase of achieving FIRE.&nbsp;</p>
<p>Instead of burning countless brain calories trying to figure out what commodities to own during inflationary times, or what US equities to own during prosperous times — FIRS automatically optimizes all of that for you.&nbsp;</p>
<p>As a fellow money nerd, I'm obsessed with understanding where my money is going and how it's working for me on a daily basis — which is why transparency is a key word used when describing this fund on their website.&nbsp;</p>
<p>At any moment, you can check out the fund's holdings — <em>broken down by weighting</em> — on their website. As of today's writing (2/28/25), some of the fund's largest Underlying ETFs include the <a href="https://www.benzinga.com/quote/SFY">SoFi Select 500 (SFY)</a>, <a href="https://www.benzinga.com/quote/MAGG">Madison Aggregate Bond ETF (MAGG)</a>, and the <a href="https://www.benzinga.com/quote/GLDM">SPDR Gold MiniShares Trust (GLDM)</a>.&nbsp;</p>
<p>If you're a fellow FIRE movement individual looking for a "set it and forget it" ETF to aid you during your Wealth Accumulation phase, FIRS might be for you.&nbsp;</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Who is Behind FIRS</h2>
<p>Michael Venuto and Daniel Weiskopf are the portfolio managers for the fund. Michael Venuto has over $8B in assets under management across all of the 55+ ETFs and 213+ SMAs he manages, and Dan Weiskopf has over $1B+ in assets under management across the 3 ETFs and 29 SMAs he manages.&nbsp;</p>
<p>Michael brings over 20 years of experience in building efficient, income-generating portfolios designed to support long-term financial freedom. Dan brings 25 years of experience to FIRE Funds and is committed to providing investors with the tools and strategies needed to support their financial goals and retire on their terms.&nbsp;</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h2 class="wp-block-heading">Investor Takeaway</h2>
<p>It has never been easier to learn about personal finance and investing — enabling people to take back control of their money and their financial futures. The FIRE movement is real, and it's here to stay.&nbsp;</p>
<p>If you're someone who's looking to participate in the FIRE movement, but the Wealth Accumulation phase is a bit too complicated for your liking — the <a href="https://www.benzinga.com/quote/FIRS">Fire Funds Wealth Builder ETF (FIRS)</a> could be a solid place to start.&nbsp;</p>
<p>Not only is it managed by industry veterans, but the strategy is simple — optimize portfolio returns no matter the market condition. I look forward to keeping tabs on the performance of this ETF over the coming quarters and years!&nbsp;</p>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<p><strong>Disclaimer:</strong> This is not financial advice or recommendation for any investment. The content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.</p>
<p><strong>Disclosure</strong>: I/we have a beneficial long position in the shares of FIRS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article. Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor.</p>














Specialty ETFs

Personal Finance

ETFs

General

FIRS: The Wealth Building ETF You Need To Achieve Financial Independence And Retire Early

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>KLA</strong>.</p>
<p>Looking at options history for KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) we detected 17 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 35% of the investors opened trades with bullish expectations and 41% with bearish.</p>
<p>From the overall spotted trades, 10 are puts, for a total amount of $751,412 and 7, calls, for a total amount of $603,700.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $610.0 and $880.0 for KLA, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for KLA's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across KLA's significant trades, within a strike price range of $610.0 to $880.0, over the past month.</p>
<h3>KLA Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741119344_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$39.5</td>
<td>$37.6</td>
<td>$37.6</td>
<td>$680.00</td>
<td>$322.9K</td>
<td align="right">23</td>
<td align="right">88</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$53.7</td>
<td>$50.6</td>
<td>$50.6</td>
<td>$790.00</td>
<td>$151.8K</td>
<td align="right">5</td>
<td align="right">30</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$49.5</td>
<td>$44.2</td>
<td>$46.9</td>
<td>$800.00</td>
<td>$140.7K</td>
<td align="right">54</td>
<td align="right">30</td>
</tr>
<tr>
<td>KLAC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$33.0</td>
<td>$32.1</td>
<td>$33.0</td>
<td>$670.00</td>
<td>$112.4K</td>
<td align="right">51</td>
<td align="right">35</td>
</tr>
<tr>
<td>KLAC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$37.0</td>
<td>$33.0</td>
<td>$34.5</td>
<td>$780.00</td>
<td>$103.5K</td>
<td align="right">36</td>
<td align="right">37</td>
</tr>
</tbody>
</table>
</p>
<h3>About KLA</h3>
<p>KLA is one of the largest semiconductor wafer fabrication equipment, or WFE, manufacturers in the world. It specializes in the market segment of semiconductor process control, wherein machines inspect semiconductor wafers during research and development and manufacturing for defects and verify precise measurements. In this section of the market, KLA holds a majority share. It also has a small exposure to the etch and deposition segments of the WFE market. It counts as top customers the largest chipmakers in the world, including TSMC and Samsung.</p>
<p>Having examined the options trading patterns of KLA, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is KLA Standing Right Now?</h3>
<ul>
<li>With a trading volume of 569,254, the price of KLAC is up by 2.49%, reaching $708.35.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 51 days from now.</li>
</ul>
<h3>What The Experts Say On KLA</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $748.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on KLA, which currently sits at a price target of $748. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for KLA with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

KLAC

What the Options Market Tells Us About KLA

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Moderna</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 26 uncommon options trades for Moderna.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 15 are puts, for a total amount of $2,799,688, and 11 are calls, for a total amount of $618,935.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $25.0 to $80.0 for Moderna over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Moderna's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $25.0 to $80.0 in the last 30 days. </p>
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741119339_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$6.35</td>
<td>$6.2</td>
<td>$6.21</td>
<td>$30.00</td>
<td>$931.5K</td>
<td>8.4K</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$13.3</td>
<td>$13.3</td>
<td>$40.00</td>
<td>$931.0K</td>
<td>9.4K</td>
<td>700</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$14.75</td>
<td>$13.45</td>
<td>$14.75</td>
<td>$40.00</td>
<td>$187.3K</td>
<td>511</td>
<td>128</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$7.25</td>
<td>$7.1</td>
<td>$7.18</td>
<td>$30.00</td>
<td>$143.9K</td>
<td>13.3K</td>
<td>237</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$25.00</td>
<td>$142.1K</td>
<td>2.0K</td>
<td>209</td>
</tr>
</tbody>
</table>
</p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<p>In light of the recent options history for Moderna, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of Moderna</h3>
<ul>
<li>With a trading volume of 5,515,339, the price of MRNA is down by -1.55%, reaching $29.8.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 58 days from now.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $49.25.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Underperform rating for Moderna, targeting a price of $34.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Moderna, targeting a price of $78.<br />
&#x2A; Reflecting concerns, an analyst from RBC Capital lowers its rating to Sector Perform with a new price target of $40.<br />
&#x2A; An analyst from Barclays has revised its rating downward to Equal-Weight, adjusting the price target to $45. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Moderna, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


MRNA

Moderna Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on Enovix. Our analysis of options history for Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) revealed 15 unusual trades.</p>
<p>Delving into the details, we found 60% of traders were bullish, while 20% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $441,332, and 8 were calls, valued at $404,942.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $9.0 to $20.0 for Enovix over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Enovix stands at 2741.07, with a total volume reaching 3,008.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Enovix, situated within the strike price corridor from $9.0 to $20.0, throughout the last 30 days.</p>
<h3>Enovix Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741119334_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$2.42</td>
<td>$1.99</td>
<td>$2.11</td>
<td>$12.00</td>
<td>$105.2K</td>
<td>50</td>
<td align="right">500</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$11.00</td>
<td>$103.1K</td>
<td>2.4K</td>
<td align="right">304</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.4</td>
<td>$10.00</td>
<td>$93.8K</td>
<td>0</td>
<td align="right">24</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.75</td>
<td>$10.00</td>
<td>$93.7K</td>
<td>4.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.25</td>
<td>$3.25</td>
<td>$11.00</td>
<td>$67.6K</td>
<td>2.4K</td>
<td align="right">694</td>
</tr>
</tbody>
</table>
</p>
<h3>About Enovix</h3>
<p>Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.</p>
<p>In light of the recent options history for Enovix, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Enovix's Current Market Status</h3>
<ul>
<li>Trading volume stands at 5,229,173, with ENVX's price up by 5.58%, positioned at $8.62.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 57 days.</li>
</ul>
<h3>What Analysts Are Saying About Enovix</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $24.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Craig-Hallum continues to hold a Buy rating for Enovix, targeting a price of $18.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $30. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enovix with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


ENVX

Unpacking the Latest Options Trading Trends in Enovix

<p>Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) has outperformed the market over the past 15 years by 6.04% on an annualized basis producing an average annual return of 17.47%. Currently, Arch Capital Group has a market capitalization of $34.87 billion. </p>
<p><strong>Buying $100 In ACGL:</strong> If an investor had bought $100 of ACGL stock 15 years ago, it would be worth <strong>$1,110.56</strong> today based on a price of $92.90 for ACGL at the time of writing.</p>
<h3>Arch Capital Group's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741119309_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

ACGL

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<p>Cryptocurrency markets have bounced back into the green on Tuesday, recovering from earlier losses as excitement builds ahead of the crypto summit on Friday.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$87,881.40</td>
<td>+2.5%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,167.42</td>
<td>+2.3%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$143.26</td>
<td>+0.6%</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.49</td>
<td>+5%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2003</td>
<td>+0.09%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001308</td>
<td>+1.1%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 32.8% and daily active addresses growing by 20.4%. Transactions greater than $100,000 are up from 10,965 to 13,388 in a single day. Exchanges netflows are up by 223.2%.</li>
<li>Coinglass data reports 295,242 traders were liquidated in the past 24 hours for $947.63 million.</li>
<li>IntoTheBlock <a href="https://x.com/intotheblock/status/1896998830375162300">data</a> shows Bitcoin's last week price drop caused a surge in active addresses, pushing the daily average to its highest level since December when Bitcoin surpassed $100,000. This uptick also coincided with an increase in zero-balance addresses, indicating capitulation.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44117695/raoul-pal-predicts-extended-crypto-cycle-into-2026-bitcoin-solana-corrections-are-typical-volatility">Raoul Pal Predicts Extended Crypto Cycle Into 2026, Bitcoin, Solana Corrections Are Typical Volatility</a></li>
<li><a href="https://in.benzinga.com/government/regulations/25/03/44100314/sec-drops-lawsuit-against-crypto-exchange-kraken-ceo-calls-it-massive-win-bayc-nft-creator-yuga-labs-also-gets-reprieve">SEC Drops Lawsuit Against Crypto Exchange Kraken, CEO Calls It, &#8216;Massive Win&#8217; — BAYC NFT Creator Yuga Labs Also Gets Reprieve</a></li>
<li><a href="https://www.benzinga.com/25/03/44105028/bybit-ceo-discloses-77-of-14-billion-stolen-funds-remain-traceable-this-and-the-coming-week-is-crucial">Bybit CEO Says 77% Of Stolen $1.4 Billion Ethereum Still Traceable After Historic Hack: &#8216;This And The Coming Week Is Critical&#8217;</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44114998/trumps-cabinet-holds-bitcoin-solana-ethereumbut-no-cardano-or-xrp">Trump&#8217;s Cabinet Holds Bitcoin, Solana, Ethereum—But No Cardano Or XRP</a></li>
<li><a href="https://www.benzinga.com/25/03/44100824/china-working-behind-closed-doors-to-create-strategic-bitcoin-reserve-says-bitcoiner-who-orange-pilled-trump">China Working Behind Closed Doors To Create Strategic Bitcoin Reserve, Says Bitcoiner Who &#8216;Orange Pilled&#8217; Trump</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Aave </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/aave/usd">AAVE</a>)</td>
<td>&nbsp;$210.82</td>
<td>+16%</td>
</tr>
<tr>
<td><strong>Cardano</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$0.9317</td>
<td>+10.8%</td>
</tr>
<tr>
<td><strong>Hedera</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>)</td>
<td>&nbsp;$0.2458</td>
<td>+8.4%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Sistine Research suggests Bitcoin is set for its final dominance pump before altseason.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Ready for final BTC dom pump before alt season. <a href="https://t.co/6rnu7b0va4">pic.twitter.com/6rnu7b0va4</a></p>
<p>&mdash; Sistine Research (@sistineresearch) <a href="https://twitter.com/sistineresearch/status/1897005241427767597?ref_src=twsrc%5Etfw">March 4, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>More Crypto Online <a href="https://x.com/Morecryptoonl/status/1897009977149284518">notes</a> BTC has hit resistance, with micro support between $83,102 and $85,877. The key breakout level is $95,170.</p>
<p>Michael van de Poppe <a href="https://x.com/CryptoMichNL/status/1896851080170065949">highlights</a> Bitcoin's rejection at $95,000, now chopping after clearing liquidity on both sides. He expects consolidation this week due to macro events and the summit on Friday.</p>
<p>CryptoAmsterdam <a href="https://x.com/damskotrades/status/1897012423116173457">sees</a> BTC looking heavy on mid-time frames after breaking down without a quick reclaim. He notes trends can shift fast but says BTC must reclaim the range low and break the trendline for momentum to improve.</p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44113146/why-the-bitcoin-pullback-may-have-a-silver-lining-for-long-term-investors">Why The Bitcoin Pullback May Have A Silver Lining For Long-Term Investors</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$AAVE

$ADA

$BTC

$DOGE

$ETH

$HBAR

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Recover Losses, Dogecoin Lags: Trader Expects Consolidation Until Friday's Crypto Summit

AVGO

MPWR

Shares of semiconductor stocks are trading higher, reversing after earlier weakness as investors assess US tariffs.

CRWD

GOOG

GOOGL

PLTR

Shares of software stocks are trading higher as tech stocks rebound following earlier market weakness.

Shares of gold stocks are trading higher amid a drop in the US dollar index.

<p><strong>Cardano</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>) has surged 40% in seven days, fueled by its unexpected inclusion in the proposed crypto strategic reserve and strong on-chain activity. Traders and analysts are now looking for <a href="https://www.benzinga.com/money/cardano-price-prediction">further upside momentum</a>.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>24-Hour Trend</strong></td>
<td><strong>7-Day Trend</strong></td>
</tr>
<tr>
<td><strong>Cardano</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/ada/usd">ADA</a>)</td>
<td>&nbsp;$0.9457</td>
<td>$33.3 billion</td>
<td>+4.8%&nbsp;</td>
<td>+42.8%&nbsp;</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.50</td>
<td>$145.3 billion</td>
<td>+1.6%&nbsp;</td>
<td>+12.9%&nbsp;</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,157.94</td>
<td>$260.4 billion</td>
<td>-1%&nbsp;</td>
<td>-10.9%&nbsp;</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>Crypto chart analyst Ali Martinez predicts ADA could rally to $2.20 if it confirms a breakout with a 12-hour candlestick close above $1.19.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/Cardano?src=hash&amp;ref_src=twsrc%5Etfw">#Cardano</a> <a href="https://twitter.com/search?q=%24ADA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$ADA</a> could be poised for a rally to $2.20! Watch for a 12-hour candlestick close above $1.19 to confirm the bullish breakout. <a href="https://t.co/0uiJyRd9qt">pic.twitter.com/0uiJyRd9qt</a></p>
<p>&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1896547356268745105?ref_src=twsrc%5Etfw">March 3, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Cardano OG &#8220;Hieronymus&#8221; <a href="https://x.com/CardanoHumpback/status/1896891745931317266">notes</a> that Cardano is the only crypto that hasn&#8217;t retraced since the U.S. Reserve announcement, saying, "There is some strength built in there."</p>
<p><strong>Statistics: </strong>Santiment <a href="https://x.com/santimentfeed/status/1896978576962150774">data</a> shows that Cardano's brief surge to $1.13 was driven by the highest whale activity in over three months. </p>
<p>A spike in transfers worth more than $100,000 led to a decline in the average token age, suggesting increased circulation of ADA on the network.</p>
<p>Coinglass data shows Cardano's liquidations spiking to all-time highs on Sunday. In the past 24 hours, liquidations stand at $37.8 million. Open interest climbed to the highest level in a month.</p>
<p>IntoTheBlock data shows Cardano large transaction volume declining by 8.2%, while daily active addresses moved higher by 0.2%.</p>
<p><strong>Community News: </strong>Cardano founder <strong>Charles Hoskinson</strong> tagged<strong> Elon Musk </strong>in an X <a href="https://x.com/IOHK_Charles/status/1896788956618125787?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1896788956618125787%7Ctwgr%5Ee8ddb7ba5fa3e7612a3adfc673a3fa5a3f958006%7Ctwcon%5Es1_&amp;ref_url=https%3A%2F%2Fthecryptobasic.com%2F2025%2F03%2F04%2Fcardano-founder-rehashes-offer-to-fix-up-dogecoin-for-x-payments%2F">post</a> on Tuesday, offering to help "fix up Dogecoin" with an old Bitcoin 2 roadmap. X Payments announced that its services will launch later this year.</p>
<p>Hoskinson <a href="https://x.com/IOHK_Charles/status/1896277229673545831">defended</a> XRP as great technology, saying that XRP has survived for a "decade through many harsh cycles and has one of the strongest communities."</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44114998/trumps-cabinet-holds-bitcoin-solana-ethereumbut-no-cardano-or-xrp">Trump&#8217;s Cabinet Holds Bitcoin, Solana, Ethereum—But No Cardano Or XRP</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Cardano Rallies 43% In Seven Days: What Is Going On With ADA?

<p>Across the recent three months, 11 analysts have shared their insights on Hologic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Hologic, revealing an average target of $83.09, a high estimate of $90.00, and a low estimate of $70.00. Highlighting a 3.05% decrease, the current average has fallen from the previous average price target of $85.70. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118472_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Hologic among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Donnelly</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$73.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Puneet Souda</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$75.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$82.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$85.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hologic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hologic compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Hologic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Hologic's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HOLX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Hologic analyst ratings.</strong></a></p>
<h2>Delving into Hologic's Background</h2>
<p>Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.</p>
<h3>Hologic: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Hologic's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.86%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Hologic's net margin excels beyond industry benchmarks, reaching <strong>19.67%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Hologic's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.06%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hologic's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>2.25%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.53</strong>, Hologic adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

HOLX

11 Analysts Have This To Say About Hologic

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Palo Alto Networks</strong>.</p>
<p>Looking at options history for Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) we detected 47 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 51% of the investors opened trades with bullish expectations and 27% with bearish.</p>
<p>From the overall spotted trades, 17 are puts, for a total amount of $1,153,338 and 30, calls, for a total amount of $1,649,282.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $205.0 for Palo Alto Networks over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Palo Alto Networks options trades today is 711.74 with a total volume of 4,857.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Palo Alto Networks's big money trades within a strike price range of $100.0 to $205.0 over the last 30 days.</p>
<h3>Palo Alto Networks Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118468_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$27.7</td>
<td>$27.35</td>
<td>$27.7</td>
<td>$165.00</td>
<td>$301.7K</td>
<td>253</td>
<td align="right">109</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$23.75</td>
<td>$22.95</td>
<td>$22.95</td>
<td>$180.00</td>
<td>$162.9K</td>
<td>60</td>
<td align="right">77</td>
</tr>
<tr>
<td>PANW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$26.75</td>
<td>$25.3</td>
<td>$25.3</td>
<td>$165.00</td>
<td>$156.8K</td>
<td>743</td>
<td align="right">0</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$10.0</td>
<td>$9.8</td>
<td>$9.9</td>
<td>$185.00</td>
<td>$137.6K</td>
<td>1.5K</td>
<td align="right">177</td>
</tr>
<tr>
<td>PANW</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$11.1</td>
<td>$10.05</td>
<td>$10.45</td>
<td>$140.00</td>
<td>$104.5K</td>
<td>38</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Palo Alto Networks</h3>
<p>Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.</p>
<p>Having examined the options trading patterns of Palo Alto Networks, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Palo Alto Networks</h3>
<ul>
<li>With a volume of 3,373,245, the price of PANW is up 0.79% at $185.14. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 76 days.</li>
</ul>
<h3>What The Experts Say On Palo Alto Networks</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $221.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Palo Alto Networks with a target price of $200.<br />
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $225.<br />
&#x2A; An analyst from Keybanc has decided to maintain their Overweight rating on Palo Alto Networks, which currently sits at a price target of $240.<br />
&#x2A; Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for Palo Alto Networks, targeting a price of $212.<br />
&#x2A; Consistent in their evaluation, an analyst from Susquehanna keeps a Positive rating on Palo Alto Networks with a target price of $230. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Palo Alto Networks options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


PANW

Palo Alto Networks's Options Frenzy: What You Need to Know

<p>Financial giants have made a conspicuous bullish move on Procter &amp; Gamble. Our analysis of options history for Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) revealed 16 unusual trades.</p>
<p>Delving into the details, we found 43% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $89,692, and 13 were calls, valued at $854,808.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $150.0 to $200.0 for Procter &amp; Gamble over the last 3 months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Procter &amp; Gamble options trades today is 1864.54 with a total volume of 6,341.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Procter &amp; Gamble's big money trades within a strike price range of $150.0 to $200.0 over the last 30 days.</p>
<h3>Procter &amp; Gamble Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118463_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.7</td>
<td>$12.55</td>
<td>$13.29</td>
<td>$180.00</td>
<td>$159.4K</td>
<td>5.1K</td>
<td>202</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.64</td>
<td>$2.43</td>
<td>$2.45</td>
<td>$195.00</td>
<td>$113.6K</td>
<td>192</td>
<td>470</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$0.79</td>
<td>$0.68</td>
<td>$0.79</td>
<td>$185.00</td>
<td>$109.7K</td>
<td>2.5K</td>
<td>1.4K</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.75</td>
<td>$9.35</td>
<td>$9.75</td>
<td>$185.00</td>
<td>$102.3K</td>
<td>2.3K</td>
<td>148</td>
</tr>
<tr>
<td>PG</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$10.7</td>
<td>$10.6</td>
<td>$10.6</td>
<td>$170.00</td>
<td>$63.6K</td>
<td>1.4K</td>
<td>85</td>
</tr>
</tbody>
</table>
</p>
<h3>About Procter &amp; Gamble</h3>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, with annual sales approaching $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.</p>
<p>Following our analysis of the options activities associated with Procter &amp; Gamble, we pivot to a closer look at the company's own performance.</p>
<h3>Procter &amp; Gamble's Current Market Status</h3>
<ul>
<li>Trading volume stands at 8,122,877, with PG's price down by -0.25%, positioned at $175.15.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 48 days.</li>
</ul>
<h3>What The Experts Say On Procter &amp; Gamble</h3>
<p>A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $172.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for Procter &amp; Gamble, targeting a price of $172. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Procter &amp; Gamble options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Market Whales and Their Recent Bets on Procter & Gamble Options

<p>Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $172.5, a high estimate of $242.00, and a low estimate of $141.00. This current average has increased by 8.92% from the previous average price target of $158.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118458_0_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Welltower by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$145.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$165.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$242.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$167.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Nicholas Yulico</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$144.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Joshua Dennerlein</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$221.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jonathan Hughes</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$155.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Omotayo Okusanya</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$141.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Welltower. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Welltower compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Welltower's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/WELL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Welltower analyst ratings.</strong></a></p>
<h2>Get to Know Welltower Better</h2>
<p>Welltower owns a diversified healthcare portfolio of 2,271 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in both Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.</p>
<h3>Welltower: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Welltower showcased positive performance, achieving a revenue growth rate of <strong>29.18%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Welltower's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.41%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Welltower's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>0.39%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Welltower's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.24%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.52</strong>, Welltower adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


WELL

What Analysts Are Saying About Welltower Stock

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Core Scientific</strong>.</p>
<p>Looking at options history for Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) we detected 27 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 59% of the investors opened trades with bullish expectations and 18% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $498,518 and 21, calls, for a total amount of $1,112,656.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $20.0 for Core Scientific over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Core Scientific's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Core Scientific's substantial trades, within a strike price spectrum from $5.0 to $20.0 over the preceding 30 days.</p>
<h3>Core Scientific Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118458_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.5</td>
<td>$12.00</td>
<td>$222.2K</td>
<td>2.7K</td>
<td align="right">5</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.6</td>
<td>$5.15</td>
<td>$5.6</td>
<td>$5.00</td>
<td>$112.0K</td>
<td>402</td>
<td align="right">2</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.5</td>
<td>$5.25</td>
<td>$5.5</td>
<td>$5.00</td>
<td>$110.0K</td>
<td>402</td>
<td align="right">602</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.5</td>
<td>$5.25</td>
<td>$5.5</td>
<td>$5.00</td>
<td>$110.0K</td>
<td>402</td>
<td align="right">402</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$5.4</td>
<td>$5.1</td>
<td>$5.4</td>
<td>$5.00</td>
<td>$108.0K</td>
<td>3</td>
<td align="right">400</td>
</tr>
</tbody>
</table>
</p>
<h3>About Core Scientific</h3>
<p>Core Scientific Inc is engaged in designing, building and operating digital infrastructure for high-performance computing. The business operates in three operating segments; Digital Asset Self-Mining, consisting of performing digital asset mining for the own account, Digital Asset Hosted Mining, consisting of providing hosting services to third parties for digital asset mining, and HPC Hosting, consisting of providing hosting services to third parties for graphics processing unit (GPU) based HPC hosting operations. The majority of revenue is derived from the Digital Asset Self-Mining Segment.</p>
<p>Having examined the options trading patterns of Core Scientific, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Core Scientific Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 22,096,493, with CORZ's price up by 0.69%, positioned at $10.21.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 64 days.</li>
</ul>
<h3>Professional Analyst Ratings for Core Scientific</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $18.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $17.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Core Scientific with a target price of $17.<br />
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for Core Scientific, targeting a price of $17.<br />
&#x2A; Maintaining their stance, an analyst from Cantor Fitzgerald continues to hold a Overweight rating for Core Scientific, targeting a price of $21.<br />
&#x2A; An analyst from Compass Point persists with their Buy rating on Core Scientific, maintaining a target price of $20. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Core Scientific with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Core Scientific, Inc. - Class A Common Stock

CORZ

Spotlight on Core Scientific: Analyzing the Surge in Options Activity

<p>Ratings for Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $3.75, a high estimate of $5.00, and a low estimate of $3.00. A 10.07% drop is evident in the current average compared to the previous average price target of $4.17. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118448_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Definitive Healthcare by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$4.50</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$3.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Underweight</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Definitive Healthcare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Definitive Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Definitive Healthcare's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Definitive Healthcare's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Definitive Healthcare analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Definitive Healthcare: A Closer Look</h2>
<p>Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.</p>
<h3>Financial Milestones: Definitive Healthcare's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Definitive Healthcare's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-5.53%</strong>. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Definitive Healthcare's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-94.84%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Definitive Healthcare's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-12.43%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Definitive Healthcare's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-5.2%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Definitive Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.57</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 4 Analyst Ratings Have To Say About Definitive Healthcare

<p>During the last three months, 6 analysts shared their evaluations of Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $285.33, a high estimate of $310.00, and a low estimate of $242.00. A decline of 8.78% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118440_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A comprehensive examination of how financial experts perceive Eagle Materials is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Brophy</td>
<td>Stifel</td>
<td>Announces</td>
<td>Hold</td>
<td>$242.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$260.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Trey Grooms</td>
<td>Stephens &amp; Co.</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$310.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Philip Ng</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$310.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eagle Materials. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Eagle Materials compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Eagle Materials's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Eagle Materials's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EXP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Eagle Materials analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Eagle Materials</h2>
<p>Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.</p>
<h3>Financial Insights: Eagle Materials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Challenges:</strong> Eagle Materials's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-0.14%</strong>. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Eagle Materials's net margin excels beyond industry benchmarks, reaching <strong>21.43%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Eagle Materials's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>8.17%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Eagle Materials's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>3.88%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Eagle Materials's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.7</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Eagle Materials Stands With Analysts

<p>During the last three months, 7 analysts shared their evaluations of G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for G-III Apparel Group, presenting an average target of $35.29, a high estimate of $40.00, and a low estimate of $29.00. Surpassing the previous average price target of $33.71, the current average has increased by 4.69%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1741118431_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of G-III Apparel Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$29.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Robert Drbul</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Ashley Owens</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$38.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to G-III Apparel Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of G-III Apparel Group compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for G-III Apparel Group's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of G-III Apparel Group's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GIII/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on G-III Apparel Group analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About G-III Apparel Group</h2>
<p>G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists primarily of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives most of its revenues from Wholesale operations.</p>
<h3>A Deep Dive into G-III Apparel Group's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> G-III Apparel Group's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately <strong>1.84%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> G-III Apparel Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>10.56%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> G-III Apparel Group's ROE excels beyond industry benchmarks, reaching <strong>7.26%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> G-III Apparel Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>4.19%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> G-III Apparel Group's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.32</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GIII

Assessing G-III Apparel Group: Insights From 7 Financial Analysts

Press Releases

Biodesix to Present at Two Investor Conferences in September

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Biodesix to Participate in Three Investor Conferences in November

Earnings

Biodesix Announces Third Quarter 2024 Results and Highlights

Health Care

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

BDSX

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

Cross Country Healthcare, Inc. - Common Stock

Cross Country Healthcare

DocGo

Enhabit

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

Fulgent Genetics

InnovAge Holding

Kindly MD

23andMe Holding

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

National Research Corporation - Common Stock

National Research

Nutex Health

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners

Prenetics Global Limited - Class A Ordinary Share

Prenetics Global

Precipio

SHL Telemedicine Ltd - American Depositary Shares

Comments

Biodesix

空売り

Biodesix (NASDAQ:BDSX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル